In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
News|Videos|July 9, 2024
Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
Author(s)Meletios A. Dimopoulos, MD
DREAMM-8 (NCT04484623) is an ongoing, randomized, open-label, phase 3 study evaluating BPd vs PVd in patients with RRMM previously treated with ≥1 line of therapy including lenalidomide.
Advertisement
Advertisement
Related to this article
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Earlier CAR T-Cell Therapy Use Highlights Sequencing and Access Considerations in Myeloma
3
CDK4/6 Inhibitors Anchor First-Line Metastatic Breast Cancer Care, But Oral SERDs May Fall Short
4
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
5